Back to Search
Start Over
The new type 2 diabetes mellitus therapy: comparison between the two classes of drugs GLPR (glucagon-like peptide receptor) agonists and SGLT2 (sodium-glucose cotransporter 2) inhibitors
- Source :
- European Heart Journal Supplements : Journal of the European Society of Cardiology
- Publication Year :
- 2020
-
Abstract
- Type 2 diabetes mellitus represents one of the most common chronic-degenerative diseases in modern society and is the cause of innumerable micro- and macrovascular complications that weigh on the national health system. Until a few years ago, there was no anti-diabetic drug that, in addition to lowering blood sugar, had an impact on cardiovascular risk in these patients. In this report, we will analyse the characteristics, contraindications, and evidence in favour of the use of two innovative categories of molecules that aim, for the first time in history, at controlling blood sugar levels and simultaneously lower cardiovascular risk in diabetics individuals: the glucagon-like peptide receptor agonists and the sodium–glucose cotransporter 2 inhibitors.
- Subjects :
- Drug
media_common.quotation_subject
Blood sugar
030209 endocrinology & metabolism
Heart failure
030204 cardiovascular system & hematology
Pharmacology
Diabete
Glucagon
03 medical and health sciences
0302 clinical medicine
GLP1 receptor agonist
Diabetes mellitus
Renin–angiotensin system
Medicine
AcademicSubjects/MED00200
media_common
business.industry
SGLT2 inhibitors
Diabetes
Type 2 Diabetes Mellitus
GLP1 receptor agonists
Articles
medicine.disease
Cardiovascular disease
Cardiovascular risk
Glucagon-like peptide-1
Cardiovascular diseases
Sodium/Glucose Cotransporter 2
Cardiology and Cardiovascular Medicine
business
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- European Heart Journal Supplements : Journal of the European Society of Cardiology
- Accession number :
- edsair.doi.dedup.....feb105dd1751be7d57dea6ce861fb1d5